Biogen Reports Two-Year Diranersen Data in Alzheimer’s Disease
Cambridge, Massachusetts, USA, November 17, 2026 Biogen has announced encouraging two-year clinical findings for diranersen, an investigational antisense oligonucleotide...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 Clinical Trial Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
Cambridge, Massachusetts, USA, November 17, 2026 Biogen has announced encouraging two-year clinical findings for diranersen, an investigational antisense oligonucleotide...
St. Louis, Missouri, USA, and Tokyo, Japan, November 10, 2026 C2N Diagnostics has entered a strategic partnership with LSI...
BOSTON, Massachusetts, October 29, 2026 CereVasc, Inc. has received approval from the U.S. Food and Drug Administration (FDA) for...
Boston, Massachusetts — October 29, 2026 CervoMed Inc. announced the publication of two peer-reviewed research articles providing additional clinical...
SEATTLE, Washington, United States — October 27, 2026 Nautilus Biotechnology, Inc., a life sciences company developing technologies for high-resolution...
SAN DIEGO — September 25, 2026 Acadia Pharmaceuticals Inc. announced topline Phase 2 results from the RADIANT clinical trial...
CRYSTAL LAKE, Ill. — September 14, 2026 Aptar Pharma and Massachusetts General Hospital (MGH) announced a research collaboration led...
San Francisco, California, September 3, 2026 Thryv Therapeutics Inc., a clinical-stage biopharmaceutical company developing selective SGK1 inhibitors, has entered...
Tokyo, Japan and Cambridge, Massachusetts, USA, September 3, 2026 Eisai Co., Ltd. and Biogen Inc. announced that China’s National...
Hong Kong, September 1, 2026 Insilico Medicine, a clinical-stage biotechnology company powered by generative artificial intelligence (AI), has announced...
